Alumis' Envudeucitinib Phase 3 Psoriasis Trials Meet All Endpoints, Demonstrating Leading Skin Clearance
Summary
Alumis Inc. announced positive topline results from its Phase 3 ONWARD clinical trials for envudeucitinib in moderate-to-severe plaque psoriasis, meeting all primary and secondary endpoints with high statistical significance and demonstrating leading skin clearance.
Key Events
-
Positive Phase 3 Results
Envudeucitinib met all primary and secondary endpoints with high statistical significance in two Phase 3 trials (ONWARD1 and ONWARD2) for moderate-to-severe plaque psoriasis.
-
Strong Efficacy Demonstrated
The drug achieved superior skin clearance compared to both placebo and apremilast, with approximately 65% of patients reaching PASI 90 and over 40% reaching PASI 100 at Week 24.
-
Favorable Safety Profile
Envudeucitinib was generally well-tolerated through Week 24, with a safety profile consistent with its Phase 2 program and no new safety signals observed.
-
NDA Submission Planned
Alumis intends to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration in the second half of 2026.
Analysis
The successful Phase 3 readout for envudeucitinib significantly de-risks Alumis' lead drug candidate, positioning it as a potential best-in-class oral therapy for plaque psoriasis. The strong efficacy data, including high rates of PASI 90 and PASI 100, combined with a favorable safety profile, supports the company's plan to submit a New Drug Application to the FDA in the second half of 2026. This milestone is crucial for the company's future revenue potential and validates its TYK2 inhibitor platform.
At the time of this filing, ALMS was trading at $9.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $867.5M. The 52-week trading range was $2.76 to $12.44. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.